Combination of anlotinib with immunotherapy enhanced both anti-angiogenesis and immune response in high-grade serous ovarian cancer

BackgroundHigh-grade serous ovarian cancer (HGSOC) poses significant treatment challenges due to frequent recurrence and resistance to conventional therapies. Combination of anlotinib with immunotherapy have showed promise in various cancers, but its impact on HGSOC remains to be fully elucidated.Me...

Full description

Saved in:
Bibliographic Details
Main Authors: Hongwei Lan, Hui Liu, Helei Hou, Chuantao Zhang, Jingjuan Zhu, Na Zhou, Xiaochun Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1539616/full
Tags: Add Tag
No Tags, Be the first to tag this record!